Rafael Holdings, Inc. (RFL) stock
RFLNYSEPharmaceutical PreparationsFiscal year ends July 31
$1.07−0.04 (-3.60%)
Close on Nov 13, 2026Market cap $55.84MP/E –Yield –
Rafael EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Rafael's EPS for the twelve months ending Jul 31, 2026 was -$0.58. For fiscal 2026 it was -$0.58. The highest annual figure on record is $0.06 in fiscal 2016.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$0.58 | – |
| FY2025 | Jul 31, 2025 | -$1.04 | – |
| FY2024 | Jul 31, 2024 | -$1.45 | – |
| FY2023 | Jul 31, 2023 | -$0.08 | – |
| FY2022 | Jul 31, 2022 | -$6.31 | – |
| FY2021 | Jul 31, 2021 | -$1.49 | – |
| FY2020 | Jul 31, 2020 | -$0.66 | – |
| FY2019 | Jul 31, 2019 | -$0.35 | – |
| FY2018 | Jul 31, 2018 | -$0.93 | -9400.0% |
| FY2017 | Jul 31, 2017 | $0.01 | -83.3% |
| FY2016 | Jul 31, 2016 | $0.06 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -$0.18 | – |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -$0.08 | – |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -$0.13 | – |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -$0.19 | – |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$0.19 | – |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -$0.19 | -176.0% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -$0.37 | – |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$0.19 | -480.0% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$1.36 | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $0.25 | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$0.15 | -314.3% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $0.05 | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$0.06 | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$0.14 | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $0.07 | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$0.23 | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$0.28 | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$0.12 | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$5.91 | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$0.71 | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$0.15 | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$0.50 | – |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -$0.09 | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | -$0.36 | – |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | -$0.14 | – |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | -$0.08 | – |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | -$0.10 | – |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -$0.16 | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -$0.07 | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -$0.08 | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -$0.04 | – |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -$0.05 | – |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -$0.04 | – |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -$0.04 | -500.0% |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -$0.74 | – |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | -$0.01 | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | -$0.01 | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | $0.01 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?